| 77.91 -1.14 (-1.44%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 96.07 | 1-year : | 112.22 |
| Resists | First : | 82.26 | Second : | 96.07 |
| Pivot price | 76.87 |
|||
| Supports | First : | 74.04 | Second : | 68.97 |
| MAs | MA(5) : | 77.91 |
MA(20) : | 76.81 |
| MA(100) : | 66.97 |
MA(250) : | 46.77 |
|
| MACD | MACD : | 2 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 70.8 |
D(3) : | 68.5 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 82.26 | Low : | 14.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ARWR ] has closed below upper band by 38.3%. Bollinger Bands are 13.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 78.82 - 79.23 | 79.23 - 79.54 |
| Low: | 75.6 - 76.02 | 76.02 - 76.34 |
| Close: | 77.24 - 77.95 | 77.95 - 78.49 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Wed, 27 May 2026
Arrowhead Pharmaceuticals (ARWR) Reveals Promising Interim Trial Results - GuruFocus
Wed, 27 May 2026
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 - Business Wire
Tue, 26 May 2026
Arrowhead Pharmaceuticals (ARWR) Reports Clinical Findings for P - GuruFocus
Tue, 26 May 2026
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Yahoo Finance
Thu, 07 May 2026
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results - Arrowhead Pharmaceuticals, Inc.
Thu, 07 May 2026
Arrowhead (NASDAQ: ARWR) swings to loss as REDEMPLO launch and big financings reshape outlook - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 141 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 88.2 (%) |
| Shares Short | 12,940 (K) |
| Shares Short P.Month | 13,000 (K) |
| EPS | -2.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.36 |
| Profit Margin | -48.4 % |
| Operating Margin | -191.6 % |
| Return on Assets (ttm) | -7.3 % |
| Return on Equity (ttm) | -42.4 % |
| Qtrly Rev. Growth | -86.5 % |
| Gross Profit (p.s.) | 4.41 |
| Sales Per Share | 4.41 |
| EBITDA (p.s.) | -1.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -34.33 |
| PEG Ratio | 0 |
| Price to Book value | 17.82 |
| Price to Sales | 17.64 |
| Price to Cash Flow | -302.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|